Therapeutic Solutions International Obtains Exclusive License for Patented Clinical Stage Adult Stem Cell for Treatment of Military and Sports Brain Injuries
July 01, 2019 09:00 ET
|
Therapeutic Solutions International, Inc.
OCEANSIDE, Calif., July 01, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Therapeutics Solutions International, Inc., (OTC: TSOI) announced recently signing of a license agreement providing exclusive...
Therapeutic Solutions International Awards Distribution of NanoStilbene and Nano Cannabidiol in Mexico to Immun ET Laboratories, LLC.
May 06, 2019 09:00 ET
|
Therapeutic Solutions International, Inc.
OCEANSIDE, Calif., May 06, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Therapeutics Solutions International, Inc., (OTC: TSOI) announced today a sales agreement for the exclusive distribution of...
Therapeutic Solutions International Continues to Refine NanoStilbene™ Formulation
February 19, 2019 09:00 ET
|
Therapeutic Solutions International, Inc.
OCEANSIDE, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Therapeutics Solutions International, Inc., (USOTC: TSOI) announced today further refinement of their patented formulation of...
Therapeutic Solutions International Continues to Expand Chronic Traumatic Encephalopathy Intellectual Property Portfolio
January 22, 2019 09:00 ET
|
Therapeutic Solutions International, Inc.
OCEANSIDE, Calif., Jan. 22, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Therapeutics Solutions International, Inc., (USOTC:TSOI) announced today an additional expansion to their CTE portfolio of...
Therapeutic Solutions International Announces Preliminary Data for Immune Stimulation in Advanced Cancer Patients by Commercially Available Product
January 14, 2019 09:00 ET
|
Therapeutic Solutions International, Inc.
OCEANSIDE, Calif., Jan. 14, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today early results of a clinical trial suggesting...
Therapeutic Solutions International Continues to Expand Chronic Traumatic Encephalopathy Intellectual Property Portfolio
January 09, 2019 11:42 ET
|
Therapeutic Solutions International, Inc.
OCEANSIDE, Calif., Jan. 09, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today the addition and expansion to their CTE...
Therapeutic Solutions International CEO Issues Shareholder Letter
December 31, 2018 09:00 ET
|
Therapeutic Solutions International, Inc.
OCEANSIDE, Calif., Dec. 31, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) addresses shareholders in letter form. We have had a...
Therapeutic Solutions International Signs Agreement for Licensing Jadi Cell's Universal Donor Adult Stem Cell Product for Chronic Traumatic Encephalopathy and Traumatic Brain Injury
December 10, 2018 09:00 ET
|
Therapeutic Solutions International, Inc.
OCEANSIDE, Calif., Dec. 10, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI) announced today the signing of an agreement between TSOI and...
Therapeutic Solutions International Expands Chronic Traumatic Encephalopathy Intellectual Property Portfolio
December 06, 2018 09:00 ET
|
Therapeutic Solutions International, Inc.
OCEANSIDE, Calif., Dec. 06, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today data demonstrating that modification of...
Therapeutic Solutions International Announces CTE Optimized NeuroStilbene Formulation
October 25, 2018 09:00 ET
|
Therapeutic Solutions International, Inc.
OCEANSIDE, Calif., Oct. 25, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today a newly optimized formulation of NeuroStilbene...